Research location

Santa Monica

California, United States

View saved research

Published trials572

Site observations632

Linked trials published572

Page1 / 12

Research activity in Santa Monica

California, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 572 trials and 632 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Santa Monica

572 linked trials · page 1 of 12

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerNCT07287098 · 2026-05-13 · 1 site observation

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)NCT07592689 · 2026-05-10 · 1 site observation

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerNCT07214532 · 2026-05-08 · 1 site observation

Mobile Vehicle-Based Delivery of Lenacapavir Pre-Exposure Prophylaxis in Los Angeles CountyNCT07467018 · 2026-04-21 · 1 site observation

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsNCT07195695 · 2026-01-16 · 2 site observations

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22 · 1 site observation

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate CancerNCT07225946 · 2025-12-19 · 1 site observation

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · 2025-12-10 · 1 site observation

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerNCT07213674 · 2025-11-28 · 1 site observation

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid TumorsNCT07229313 · 2025-11-13 · 1 site observation

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerNCT07173751 · 2025-10-30 · 1 site observation

Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart FailureNCT07069738 · 2025-10-22 · 1 site observation

A Study of ZW251 in Participants With Advanced Solid TumorsNCT07164313 · 2025-10-21 · 1 site observation

Effects of Transcranial Focused Ultrasound Stimulation (tFUS) on Neurological and Cognitive Outcomes in Parkinson's DiseaseNCT07207122 · 2025-10-08 · 1 site observation

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.NCT07028853 · 2025-09-28 · 1 site observation

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabNCT06876714 · 2025-09-17 · 1 site observation

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsNCT07090499 · 2025-08-20 · 2 site observations

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid TumorsNCT07085091 · 2025-08-18 · 1 site observation

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)NCT07098338 · 2025-08-07 · 1 site observation

A Study of LY4257496 in Participants With Cancer (OMNIRAY)NCT07114601 · 2025-08-06 · 1 site observation

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerNCT07005102 · 2025-08-03 · 1 site observation

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsNCT07094204 · 2025-07-25 · 1 site observation

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerNCT06892548 · 2025-05-02 · 1 site observation

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)NCT06858813 · 2025-04-14 · 1 site observation

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)NCT06797635 · 2025-03-20 · 1 site observation

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsNCT06772623 · 2025-03-06 · 1 site observation

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted TherapyNCT06780670 · 2025-02-27 · 1 site observation

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid TumorsNCT06789172 · 2025-01-23 · 1 site observation

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)NCT06524830 · 2024-12-30 · 1 site observation

A First-in-Human Study of MEN2312 in Adults With Advanced Breast CancerNCT06638307 · 2024-10-25 · 1 site observation

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%NCT06561386 · 2024-10-07 · 1 site observation

A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsNCT06561685 · 2024-09-19 · 1 site observation

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsNCT06586515 · 2024-09-12 · 1 site observation

Starting Technology in At Risk Type 1 Diabetes StudyNCT06453928 · 2024-09-05 · 1 site observation

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)NCT06452277 · 2024-08-28 · 1 site observation

SW-682 in Advanced Solid TumorsNCT06251310 · 2024-07-31 · 1 site observation

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.NCT06590857 · 2024-07-19 · 1 site observation

Global Paradise System US Post Approval StudyNCT06297291 · 2024-06-28 · 1 site observation

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung CancerNCT06343402 · 2024-05-22 · 1 site observation

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerNCT06350097 · 2024-04-29 · 1 site observation

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationNCT06179160 · 2024-01-04 · 1 site observation

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.NCT06072612 · 2023-12-05 · 3 site observations

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerNCT06058377 · 2023-11-27 · 1 site observation

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsNCT05899608 · 2023-10-26 · 1 site observation

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerNCT05929768 · 2023-09-15 · 1 site observation

A Study of DB-1310 in Advanced/Metastatic Solid TumorsNCT05785741 · 2023-08-17 · 1 site observation

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsNCT05914116 · 2023-08-17 · 1 site observation

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate CancerNCT05803941 · 2023-08-14 · 1 site observation

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid TumorsNCT05983432 · 2023-08-08 · 1 site observation

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationNCT05877599 · 2023-07-12 · 1 site observation

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.